Shattuck expands SL-325 development into hidradenitis suppurativa

• Shattuck Labs (NASDAQ:STTK) plans a Phase 2 trial evaluating SL-325 in patients with moderate to severe hidradenitis suppurativa (HS).
• The RECEPTIVE-HS1 trial is expected to enroll approximately 150 patients, with Week 16 results anticipated in the first half of 2028.
• Shattuck expects its current cash position to fund operations into 2029.

Shattuck Labs (NASDAQ:STTK) announced plans to evaluate SL-325 in a Phase 2 clinical trial for patients with moderate to severe hidradenitis suppurativa (HS), expanding the program beyond its existing inflammatory bowel disease development.

The company expects the RECEPTIVE-HS1 trial to begin in 2026, with an investigational new drug (IND) application submission planned for October 2026 and Week 16 trial results expected in the first half of 2028.

The randomized, double-blind Phase 2 study will compare two SL-325 dose levels against placebo and is expected to enroll approximately 150 patients.

Participants will undergo a 16-week placebo-controlled treatment period followed by an SL-325 extension through Week 52.

The primary endpoint will evaluate the proportion of patients achieving at least a 50% reduction in abscesses and inflammatory nodules without worsening abscess or draining tunnel counts.

Shattuck appointed Shoba Ravichandran as clinical development head to lead the HS program and stated that existing cash resources are expected to support operations into 2029.